These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Methicillin-resistant Staphylococcus aureus. Lifson A; Paul B West J Med; 1984 Nov; 141(5):690. PubMed ID: 6569780 [No Abstract] [Full Text] [Related]
65. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Lucet JC; Herrmann M; Rohner P; Auckenthaler R; Waldvogel FA; Lew DP Antimicrob Agents Chemother; 1990 Dec; 34(12):2312-7. PubMed ID: 2128441 [TBL] [Abstract][Full Text] [Related]
66. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Murillo O; Doménech A; Garcia A; Tubau F; Cabellos C; Gudiol F; Ariza J Antimicrob Agents Chemother; 2006 Dec; 50(12):4011-7. PubMed ID: 17015630 [TBL] [Abstract][Full Text] [Related]
67. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Burnie J; Matthews R; Jiman-Fatami A; Gottardello P; Hodgetts S; D'arcy S Clin Infect Dis; 2000 Sep; 31(3):684-9. PubMed ID: 11017816 [TBL] [Abstract][Full Text] [Related]
68. Drug resistance pattern of methicillin resistant Staphylococcus aureus. Pal N; Ayyagari A Indian Pediatr; 1991 Jul; 28(7):725-9. PubMed ID: 1800344 [TBL] [Abstract][Full Text] [Related]
69. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis. Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565 [TBL] [Abstract][Full Text] [Related]
70. [Do we have adequate antimicrobials against methicillin-resistant Staphylococcus aureus?]. Muñoz Bellido JL; García-Rodríguez JA Rev Esp Quimioter; 2006 Dec; 19(4):313-6. PubMed ID: 17235398 [No Abstract] [Full Text] [Related]
72. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Loffler CA; Macdougall C Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081 [TBL] [Abstract][Full Text] [Related]
73. An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus. Arnold FW; Wojda B J Ky Med Assoc; 2005 May; 103(5):206-10. PubMed ID: 15918650 [TBL] [Abstract][Full Text] [Related]
74. Is vancomycin obsolete? Legendre D Am J Health Syst Pharm; 2009 Jun; 66(11):977-8. PubMed ID: 19451604 [No Abstract] [Full Text] [Related]
75. Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Simon GL; Smith RH; Sande MA Rev Infect Dis; 1983; 5 Suppl 3():S507-8. PubMed ID: 6635441 [No Abstract] [Full Text] [Related]
76. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Chambers HF Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879 [TBL] [Abstract][Full Text] [Related]
77. Inducible clindamycin and methicillin resistant Staphylococcus aureus in a tertiary care hospital, Kathmandu, Nepal. Adhikari RP; Shrestha S; Barakoti A; Amatya R BMC Infect Dis; 2017 Jul; 17(1):483. PubMed ID: 28693489 [TBL] [Abstract][Full Text] [Related]
78. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin. Apisarnthanarak A; Mundy LM Int J Infect Dis; 2007 May; 11(3):283-4. PubMed ID: 16876452 [No Abstract] [Full Text] [Related]
79. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus. Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411 [TBL] [Abstract][Full Text] [Related]